Can KDM6A Mutations Help Guide Treatment Selection in Bladder Cancer

Mutations in KDM6A have been identified as a regulator of therapeutic responses in patients with advanced bladder cancer, sensitizing tumors to anti–PD-1 immune checkpoint inhibition but resisting cisplatin chemotherapy, according to…